Briefly, tumor cells in AITL/FHTCL demonstrated a very characteristic immunophenotypic signature with positive expressions of CD2, CD4, CD5, CD45, and heterogeneous CD7 but negative expressions of surface CD3, CD8, CD16, CD56, CD25, CD26, and CD30. Here, NCAM1 is linked to neoplasm.